Cargando…

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Fierro, Luca, Nesheiwat, Nora, Naik, Hetanshi, Mistry, Pramod K., Balwani, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849572/ http://dx.doi.org/10.1016/j.ymgme.2020.12.077

Ejemplares similares

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

The N370S/R496H genotype in type 1 Gaucher disease – Natural history and implications for pre symptomatic diagnosis and counseling
por: Zeid, Natasha, et al.
Publicado: (2020)

The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system
por: Narayanan, Praveena, et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

eP187: Decentralization of clinical trials in the era of COVID-19: Implications for rare disease trials
por: Manjrekar, Kriti, et al.
Publicado: (2022)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Impact of SARS-CoV-2 infection on Gaucher disease patients in Italy
por: Cappellini, Maria Domenica, et al.
Publicado: (2021)

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
por: McClenaghan, Elliot, et al.
Publicado: (2020)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

Parkinson's disease prevalence in Fabry disease: A survey study
por: Wise, Adina H., et al.
Publicado: (2017)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report
por: Vujosevic, Snezana, et al.
Publicado: (2019)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria
por: Balwani, Manisha, et al.
Publicado: (2022)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
por: Rosenberg, Eli S., et al.
Publicado: (2020)

Analysis of SARS-CoV-2 RNA on surfaces in New York City
por: Karani, Rabia, et al.
Publicado: (2021)

Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA
por: Liu, Dakai, et al.
Publicado: (2023)

Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics
por: Colson, Philippe, et al.
Publicado: (2022)

Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?
por: Andrade-Campos, Marcio, et al.
Publicado: (2020)

SARS-CoV-2 IgG antibody responses in New York City
por: Reifer, Josh, et al.
Publicado: (2020)

Introductions and early spread of SARS-CoV-2 in the New York City area
por: Gonzalez-Reiche, Ana S., et al.
Publicado: (2020)

Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries
por: Hůlková, Helena, et al.
Publicado: (2010)

Enfermedad de Gaucher : revisión bibliográfica y presentación de dos casos
por: Bello Martínez, Nora Ivette
Publicado: (2006)

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
por: Drelichman, Guillermo, et al.
Publicado: (2019)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave
por: Hernandez, Matthew M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jo0tpt7dbevesr54csnoc937mu